List of Excipients in Branded Drug INLYTA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	HYPROMELLOSE 2910
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	LACTOSE MONOHYDRATE
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	INLYTA	axitinib	0069-0145	TITANIUM DIOXIDE

INLYTA Excipient Strategy, Patent Protection, Generic Risk, and Commercial Opportunities

Last updated: September 26, 2026

INLYTA is Pfizer’s oral axitinib product for advanced renal cell carcinoma. Its formulation uses conventional, low-cost solid-dose excipients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and a film-coating system. The primary commercial opportunity is not a novel excipient platform. It is supply security, low-cost generic manufacture, differentiated dose flexibility, and formulation improvements that address axitinib’s narrow exposure target and dose-adjustment requirements.

Axitinib is a small-molecule tyrosine kinase inhibitor, not a biologic. Biosimilar competition is therefore irrelevant. The principal threats are abbreviated new drug applications, patent challenges, manufacturing scale-up, and substitution into the 1-mg and 5-mg tablet strengths.

What excipients are used in INLYTA tablets?

The INLYTA tablet core contains conventional excipients used to support direct compression, tablet disintegration, lubrication, and dose uniformity. Pfizer’s U.S. prescribing information identifies the following inactive ingredients:[1]

Component	Function in the formulation	Commercial relevance
Microcrystalline cellulose	Diluent and dry-binder	Widely available; supports direct compression and tablet strength
Lactose monohydrate	Diluent and bulking agent	Low cost but relevant to lactose-intolerant patients and supplier qualification
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and dissolution
Magnesium stearate	Lubricant	Controls ejection force but can affect wetting and dissolution if over-lubricated
Film-coating materials	Color, protection, swallowability, and product identification	Supports differentiation of 1-mg and 5-mg strengths

INLYTA is marketed as immediate-release film-coated tablets in 1-mg and 5-mg strengths. The tablets are intended for oral administration twice daily, with or without food, subject to dose modification.[1]

Why does the INLYTA excipient system matter?

The formulation has several technical characteristics relevant to generic development:

1. Axitinib is a potent drug administered at a low milligram dose.
2. Dose uniformity is therefore more important than bulk drug loading.
3. The product must support multiple dose levels and frequent titration.
4. Exposure can change with strong CYP3A4/5 inhibitors, strong CYP3A4/5 inducers, hepatic impairment, and selected food conditions.[1]
5. Tablet disintegration and dissolution must remain consistent despite the low active-ingredient concentration.

The public formulation profile does not indicate reliance on a novel controlled-release matrix, lipid system, amorphous dispersion, or complex multiparticulate technology. That reduces the technical barrier to generic development compared with products protected by modified-release or drug-device systems.

What formulation strategy does INLYTA use?

INLYTA uses a conventional immediate-release tablet strategy rather than a delivery system designed to prolong release. The formulation priorities are dose uniformity, mechanical strength, rapid disintegration, acceptable dissolution, and stable film coating.

What manufacturing process is likely to be used?

The listed excipients are compatible with a conventional powder-blending and compression process, followed by film coating. A generic manufacturer could use direct compression or a granulation-based process, depending on:

• Axitinib particle size and flowability.
• Content-uniformity performance at the 1-mg strength.
• Powder segregation during blending and transfer.
• Tablet tensile strength and friability.
• Lubrication sensitivity.
• Coating uniformity at small tablet sizes.
• Dissolution matching against the reference product.

The principal manufacturing challenge is unlikely to be excipient availability. It is the control of low-dose active distribution and the demonstration that the finished product meets pharmaceutical equivalence and bioequivalence requirements.

Are the excipients protected by intellectual property?

The individual excipients are established pharmaceutical materials and generally are not proprietary to INLYTA. A supplier may have separate rights in a branded coating premix, particle-engineered grade, or manufacturing process, but those rights would not ordinarily prevent a generic manufacturer from using functionally equivalent excipients.

The commercially relevant intellectual-property questions concern axitinib, formulation claims, methods of treatment, manufacturing processes, and regulatory exclusivity. The basic use of microcrystalline cellulose, lactose, croscarmellose sodium, and magnesium stearate is not a meaningful standalone barrier.

What commercial opportunities exist for INLYTA excipients?

The largest opportunities are in excipient supply, formulation development, and generic manufacturing support.

Excipient supply opportunities

Suppliers can compete for qualified sources of:

• Low-moisture microcrystalline cellulose.
• Consistent particle-size grades of lactose monohydrate.
• High-performance croscarmellose sodium.
• Pharmaceutical-grade magnesium stearate.
• Film-coating systems matching the reference-product color and opacity.

Supplier value is strongest where it reduces variability in content uniformity, dissolution, tablet compression, or coating performance. Price alone is less decisive during development because switching excipient grades can trigger comparative testing, stability work, and manufacturing requalification.

Formulation-development opportunities

A generic developer may improve the formulation by using:

• Co-processed excipients for better flow and content uniformity.
• Spray-dried lactose or engineered cellulose to improve direct compression.
• Alternative superdisintegrants to manage dissolution.
• Lower-magnesium-stearate systems to improve wetting.
• Taste-masking or swallowability improvements.
• Smaller tablets or optimized tablet geometry.
• Packaging and moisture-control systems that improve shelf life.

These changes are commercially useful only if they preserve bioequivalence, dissolution performance, stability, and manufacturability. A technically superior formulation does not automatically create enforceable exclusivity.

Dose-flexibility opportunities

Axitinib treatment commonly requires dose escalation or reduction. The commercial product has 1-mg and 5-mg strengths, which support titration around the standard 5-mg twice-daily dose.[1]

Potential product opportunities include:

Opportunity	Commercial rationale	Key barrier
Lower-dose tablet presentations	Supports reductions for adverse events or drug interactions	Market size and regulatory justification
Dose-combination packaging	Simplifies titration and reduces dispensing errors	Inventory complexity
Calendar or titration packs	Aligns packaging with dose-escalation protocols	Reimbursement and prescriber adoption
Smaller or easier-to-swallow tablets	Addresses adherence and swallowing issues	Demonstrating equivalent performance
Unit-dose blister packaging	Supports oncology adherence and handling	Packaging cost
Hospital or specialty-pharmacy packs	Reduces dispensing friction	Channel economics

A reformulated axitinib product would need a clear clinical or operational advantage. A new excipient alone is unlikely to justify a premium price.

When does INLYTA lose exclusivity?

INLYTA’s principal commercial exclusivity is governed by the combined effect of FDA regulatory exclusivity and listed patents. FDA approved axitinib tablets in January 2012 for advanced renal cell carcinoma after failure of one prior systemic therapy.[2]

Milestone	Date or status
U.S. active ingredient	Axitinib
Brand	INLYTA
Sponsor	Pfizer
U.S. approval	January 2012
Dosage form	Immediate-release film-coated tablet
Strengths	1 mg and 5 mg
Regulatory pathway for competitors	ANDA, subject to patent certification and FDA requirements
Biologic status	Small molecule; biosimilar pathway does not apply
Core commercial risk	Generic axitinib after relevant patent and regulatory barriers

The exact launch date for a generic depends on the patents listed in the FDA Orange Book, the filing dates of ANDAs, Paragraph IV certifications, litigation outcomes, and any settlement agreements. The Orange Book remains the controlling public source for the current listed-patent position.[3]

What is the Orange Book status of INLYTA?

The Orange Book identifies patents associated with approved drug products and provides expiration information used in ANDA patent-certification analysis.[3] INLYTA’s relevant listing must be reviewed by product number and patent listing because formulation, method-of-use, and pediatric exclusivity issues can affect the earliest lawful generic entry date.

For commercial diligence, the critical questions are:

• Which patents are currently listed against INLYTA?
• Which patents cover the active ingredient rather than only a method of treatment?
• Are any listed patents expired, delisted, or subject to a statutory stay?
• Have ANDA applicants filed Paragraph IV certifications?
• Has Pfizer sued within the 45-day period?
• Are any settlements subject to Federal Trade Commission review?
• Does pediatric exclusivity add six months to an otherwise expiring period?

A patent expiration date alone does not establish the first generic launch date. The practical entry date can be earlier through a settlement, later because of litigation, or limited by remaining regulatory exclusivity.

What patents protect axitinib and INLYTA?

Axitinib protection has historically included composition-of-matter and use-related rights associated with the molecule and its treatment of cancer. Public patent records must be reconciled across the U.S. Patent and Trademark Office, FDA Orange Book, and litigation dockets because patent families can contain continuations, terminal disclaimers, and claims with different scope.[3-5]

The most important categories are:

Composition-of-matter patents

These patents can provide the strongest protection because they cover axitinib or a defined chemical genus that includes it. If enforceable claims remain active, a generic manufacturer cannot ordinarily avoid infringement merely by changing excipients.

Method-of-use patents

Method patents may cover treatment of renal cell carcinoma, dosing regimens, patient selection, or use after prior therapy. Their commercial impact depends on claim scope, prescribing behavior, label language, induced-infringement risk, and the feasibility of a section viii carve-out.

Formulation patents

The public INLYTA formulation is conventional. Any formulation patent would need to protect a specific composition, dissolution profile, particle-size distribution, process, or stability characteristic rather than the ordinary use of common excipients. The practical strength of such patents depends on whether a generic can design around the claim while maintaining bioequivalence.

Manufacturing patents

Process claims may cover crystallization, polymorph control, particle engineering, impurity control, or scale-up methods. These rights can increase the cost of active pharmaceutical ingredient production but are less likely than composition patents to block every generic route.

What Paragraph IV challenges and litigation affect INLYTA?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the brand sponsor files suit within 45 days, FDA approval of the ANDA is generally subject to a 30-month stay, subject to statutory exceptions and court action.[6]

For INLYTA, the relevant litigation analysis should separate:

Issue	Business effect
Paragraph IV filing	Signals a potential early generic launch
Patent litigation	Can delay approval or create settlement leverage
Section viii statement	May permit approval for non-patented uses if labeling is carved out
First-filer status	May create 180-day generic exclusivity if statutory conditions are met
Settlement agreement	Can establish an agreed generic entry date
At-risk launch	Exposes the generic to damages and injunction risk
Patent delisting or claim narrowing	Can reduce the brand’s litigation leverage

No biosimilar litigation framework applies because axitinib is a chemically synthesized small molecule. The competitive pathway is generic substitution under the ANDA system.

Which companies are challenging INLYTA?

Potential challengers are typically identified through FDA ANDA records, Paragraph IV notices, federal court filings, and commercial generic databases. Publicly available information can change as ANDAs are filed, withdrawn, transferred, or settled.

The relevant competitor groups include:

• Large generic manufacturers with oncology portfolios.
• Specialty generic companies focused on high-value oral oncology products.
• Contract manufacturers supplying finished-dose axitinib.
• API producers with axitinib process capability.
• Regional companies pursuing non-U.S. approvals.

A competitor’s ability to launch depends on more than FDA approval. It must secure qualified axitinib API, demonstrate low-dose content uniformity, produce both commercial strengths, satisfy stability requirements, and obtain pharmacy or specialty-distributor access.

How strong is the INLYTA patent estate?

The estate is strongest where it relies on active composition-of-matter claims and weaker where protection depends only on conventional excipients or narrow formulation claims.

Patent category	Likely strength	Generic design-around potential
Axitinib composition	High while enforceable	Low
Specific therapeutic use	Moderate to high, claim-dependent	Moderate through labeling and prescribing controls
Immediate-release tablet with common excipients	Low to moderate	High
Specific particle size or polymorph	Moderate	Moderate
Manufacturing process	Moderate	Moderate to high
Packaging or color system	Low	High

The absence of a complex delivery system lowers the formulation barrier. Commercial protection therefore depends heavily on the status of active patents and any litigation settlements.

What is the FDA regulatory status of INLYTA?

FDA approved INLYTA for adults with advanced renal cell carcinoma after failure of one prior systemic therapy.[2] The product is an oral tablet, and its label includes dose modification instructions, drug-interaction warnings, hepatic-impairment considerations, and adverse-event management.[1]

The FDA regulatory issues most relevant to competitors are:

• Pharmaceutical equivalence to the reference listed drug.
• Bioequivalence under the ANDA pathway.
• Matching the 1-mg and 5-mg strengths.
• Demonstrating dissolution across relevant media.
• Stability of the finished tablets.
• Appropriate labeling and any method-of-use carve-outs.
• Compliance with current good manufacturing practice.

How does INLYTA compare with competing renal cell carcinoma drugs?

INLYTA competes with oral VEGF-directed therapies and combination regimens, including cabozantinib, pazopanib, lenvatinib combinations, and immune checkpoint inhibitor-based treatments. The competitive distinction is clinical positioning rather than excipient technology.

Product	Active ingredient	Form	Main formulation implication
INLYTA	Axitinib	Immediate-release tablet	Conventional low-dose oral tablet
CABOMETYX	Cabozantinib	Tablet	Different active ingredient and patent estate
VOTRIENT	Pazopanib	Tablet	Conventional oral solid dose with separate food and interaction considerations
LENVIMA	Lenvatinib	Capsule	Different dosage form and capsule manufacturing
OPDIVO/YERVOY regimens	Nivolumab/ipilimumab	Injectable biologics	Biosimilar and biologic competition, not relevant to axitinib

INLYTA’s excipient opportunity is therefore primarily a cost, quality, and adherence opportunity. It is not a platform opportunity comparable with long-acting injectables or complex biologic delivery systems.

What generic entry risks exist for INLYTA?

The main scenarios are:

1. A generic launches after expiration or settlement of the last blocking patent.
2. A first Paragraph IV filer receives 180-day exclusivity, delaying broader generic competition.
3. Multiple manufacturers launch after the blocking period, causing rapid price erosion.
4. A generic launches with a section viii carve-out that excludes protected use language.
5. A company pursues an at-risk launch and faces damages or injunctive relief.
6. Non-U.S. manufacturers enter markets with shorter or different patent terms.

Price pressure is likely to be highest after multiple ANDA approvals. The 1-mg and 5-mg strengths create manufacturing and inventory requirements but do not establish a durable barrier if both are readily reproducible.

What licensing deals and commercial partnerships affect axitinib?

Axitinib was developed and commercialized by Pfizer. The commercial value chain includes Pfizer, API suppliers, contract manufacturers, specialty distributors, oncology pharmacies, and generic developers.

The most material partnership opportunities are likely to involve:

• Regional commercialization rights.
• Generic or authorized-generic manufacturing.
• API supply and dual sourcing.
• Specialty-pharmacy distribution.
• Dose-packaging systems.
• Formulation development for markets with limited access.
• Combination-therapy development.

A licensing transaction based solely on a conventional excipient formulation would have limited value unless it delivers a regulatory advantage, improved stability, reduced cost of goods, or clinically meaningful adherence benefits.

Key Takeaways

• INLYTA is an immediate-release axitinib tablet in 1-mg and 5-mg strengths.
• Its core excipients are conventional: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.
• The formulation is technically accessible to generic manufacturers, with low-dose content uniformity as the main development challenge.
• The principal commercial defenses are active axitinib patents, method-of-use rights, litigation outcomes, and settlement timing.
• Biosimilar risk does not apply because axitinib is a small molecule.
• Excipient suppliers can compete through consistency, qualification support, dissolution control, and supply reliability.
• The strongest formulation opportunities involve dose flexibility, packaging, adherence, and manufacturing efficiency rather than a new excipient alone.
• Generic launch timing must be determined from current Orange Book listings, ANDA certifications, litigation, and settlements.

FAQs

Can a generic manufacturer use different excipients from INLYTA?

Yes. An ANDA applicant can use different inactive ingredients if the product meets applicable safety, quality, pharmaceutical-equivalence, dissolution, stability, and bioequivalence requirements.

Does lactose in INLYTA create a meaningful patient or market limitation?

Lactose may matter for patients with specific intolerance or excipient sensitivities, but its presence does not generally create a broad commercial barrier. A lactose-free generic could be differentiated if it provides a clear labeling or patient-access benefit.

Is axitinib suitable for an amorphous solid-dispersion formulation?

It may be technically possible, but the commercial case depends on whether the new system improves exposure, reduces variability, or enables a clinically useful dose. A more complex formulation would increase development and manufacturing costs.

Can an excipient change support a new patent for axitinib?

Potentially, but only if the formulation produces patentable and defensible technical features, such as a defined composition, particle state, dissolution profile, stability result, or pharmacokinetic advantage. Routine substitution of one standard excipient for another is unlikely to provide strong protection.

What is the most attractive commercial opportunity after generic entry?

The strongest opportunities are usually low-cost, reliable production of both strengths, supply-chain redundancy, specialty-pharmacy packaging, and differentiated formulations that support dose titration or swallowing. Price competition will limit the value of undifferentiated tablets.

References

1. Pfizer Inc. (2024). INLYTA (axitinib) tablets, for oral use: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2012). FDA approves INLYTA for advanced kidney cancer. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

5. U.S. Patent and Trademark Office. (2024). Patent Public Search. https://ppubs.uspto.gov/pubwebapp/

6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications. https://www.fda.gov